Millington-Ward Sophia, McMahon Helena P, Farrar G Jane
Department of Genetics, Trinity College Dublin, Dublin 2, Ireland.
Trends Mol Med. 2005 Jun;11(6):299-305. doi: 10.1016/j.molmed.2005.04.006.
Osteogenesis imperfecta (OI) is an incurable genetic brittle-bone disease. Although drug therapy, surgery and physiotherapy represent current treatments for OI, the search is ongoing for effective and innovative new therapies targeting the underlying causes of the disease. In this regard, recent advances in the fields of gene and stem-cell therapies have been considerable. In spite of the many challenges that remain, potential new therapies for OI, which have been tested in cell culture systems, animal models and patients, offer hope for the future development of successful therapies. Recent progress in the field is reviewed here.
成骨不全症(OI)是一种无法治愈的遗传性脆骨病。尽管药物治疗、手术和物理治疗是目前针对成骨不全症的治疗方法,但人们仍在不断寻找针对该疾病根本病因的有效且创新的新疗法。在这方面,基因和干细胞治疗领域最近取得了相当大的进展。尽管仍存在许多挑战,但已经在细胞培养系统、动物模型和患者身上进行测试的成骨不全症潜在新疗法,为成功疗法的未来发展带来了希望。本文将对该领域的最新进展进行综述。